Body mass index (BMI) does not predict responses to psilocybin
Background Psilocybin is a serotonin type 2A (5-HT2A) receptor agonist and naturally occurring psychedelic. 5-HT2A receptor density is known to be associated with body mass…
Category: Psilocybin
Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis
Psilocybin is an emerging potential therapy for the treatment of psychiatric illnesses. Microdosing has been shown to result in an overall improvement in patients with…
Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis
Moving towards a systems psychiatry paradigm embraces the inherent complex interactions across all levels from micro to macro and necessitates an integrated approach to treatment.…
Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial
Background Psilocybin has been suggested as a novel, rapid-acting treatment for depression. Two consecutive doses have been shown to markedly decrease symptom severity in an…
Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants
Psilocybin is being investigated as a potential treatment for psychiatric and neurological disorders. Only a few studies have evaluated the pharmacokinetics (PKs) of psilocybin and…
Are psychedelics the answer to chronic pain: A review of current literature
Aims We aim to provide an evidence-based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin. Content Chronic pain is a…
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life
Background COMP360 is a proprietary, synthetic formulation of psilocybin being developed for treatment-resistant depression (TRD), a burdensome, life-threatening illness with high global impact. Here, we…
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major…
Acute psilocybin enhances cognitive flexibility in rats
Psilocybin has been shown to improve symptoms of depression and anxiety when combined with psychotherapy or other clinician-guided interventions. To understand the neural basis for…
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Introduction Small-scale clinical studies with psychedelic drugs have shown promising results for the treatment of several mental disorders. Before psychedelics become registered medicines, it is…